梅里埃诊断产品(上海)有限公司

  • 所属行业:医疗设备/器械
  • 企业规模:101-500人
  • 企业性质:外企独资

Marketing Intern(上海总部,市场部)

  • 工作地点:上海
  • 有效日期:2017年08月07日 至 2017年09月06日
  • 招聘人数:1 人
  • 职位性质:兼职/实习

Marketing Intern 职位描述:

该职位已过期或已暂停

梅里埃诊断产品(上海)有限公司其他最新招聘

职位名称 工作地点 职位类型 发布日期 所属机构
Digital Marketing Intern 上海 兼职/实习 8月24日 上海总部
Sales Management Intern销售副总裁助理实习生 上海 兼职/实习 8月23日 上海总部
Legal Intern 上海 兼职/实习 8月23日 上海总部
QMS 质量部实习生 上海 兼职/实习 8月15日 上海总部
Commercial Operation Intern 上海 兼职/实习 8月09日 上海总部
Customer Service Intern 上海 兼职/实习 8月07日 上海总部

公司简介

梅里埃诊断产品(上海)有限公司

Introduction of bioMerieux
生物梅里埃公司创建於1963年,公司依赖自身的科技研究和工业生产资源,始终致力於开发作为医疗和工业用途的体外诊断产品。 集团专门设计、开发、生产和推广应用在临床和工业的系统。生物梅里埃的诊断系统是由试剂、 仪器和软件组成,主要是为传染病、工业微生物控制、心血管病和肿瘤病等四个主要策略性领域来设计。
在2007年,公司销售额为10亿6千3百万欧元,集团共有11个生产基地和9个研究中心,分布于欧洲、北美洲和南美洲。集团全球拥有38个办事处,至2007年12月31日集团员工超过5,700人。
生物梅里埃公司产品有两个应用领域 : 临床和工业,临床市场占总销售额的85.5%,而工业市场占14.5%。工业的应用主要在食品、药品和化妆品的微生物分析,增长非常迅速,生物梅里埃是全球体外诊断领域的第八大生产商。
生物梅里埃中国有限公司已经20年的发展,自动化微生物鉴定分析系统的用户已达1400余家,自动微生物培养系统已达700余家,全自动细菌计数系统60余台,手工产品用户覆盖全国的省市70%以上。同时公司拥有数十名微生物临床及工业领域专业人员和工程技术人员,其中许多人员都来自检验一线,拥有丰富的检验经验和仪器维修经验。全面负责生物梅里埃公司产品的销售,仪器的安装、维护及保养,以及用户的培训及技术支持。
生物梅里埃公司拥有完善的产品策略、销售策略和市场发展策略以全面的技术支持作後盾,为用户提供感染病检测产品及“全面解决问题”的服务是生物梅里埃公司的宗旨。相信会为您提供不断完善的产品和令您满意的服务。
bioMérieux by Alain Mérieux
bioMérieux’s mission is to contribute to the improvement of public health worldwide through in vitro diagnostics. Throughout its history, our company has committed to four priorities, which today, represent its strength:
• Our independence and expertise in the field of in vitro diagnostics allow us to respond rapidly in today’s complex environment and to form partnerships that are vital to our scientific and international growth.
• Our international scope, with 84% of sales coming from outside of France. Established in 150 countries, with 39 subsidiaries and an extensive network of distributors, we are close to our customers, wherever they may be, and provide a line of products tailored to the realities of each region.
• 45 years of experience and know-how in the field of infectious diseases allows bioMérieux, a world leader in microbiology, to respond to major public health issues, and affirm its position as a key player in clinical diagnostics and industrial microbiological quality control.
• Scientific and technological innovation is at the heart of the bioMérieux strategy. It has enabled us to extend our expertise to the fields of cancer and cardiovascular diseases, complementing that of infectious diseases. bioMérieux dedicates considerable resources to R&D (over 12% of its sales), pursuing an ambitious policy based on multidisciplinary internal teams and a network of international partnerships and scientific affiliations.
bioMérieux is part of the Mérieux Alliance group, the mission of which is to provide health professionals with innovative solutions, derived from biology, and spanning the range of healthcare: prevention, diagnosis, prognosis, immunotherapy and clinical follow-up.

bioMérieux is committed to serving a medicine that is continually more reactive, preventive and personalized in order to improve the quality of patient care. This is why our teams are located all over the world. They are at work developing diagnostic systems and reagents that respond perfectly to the demands of physicians and biologists, while anticipating scientific and technological developments. We also rely on the support of our shareholders, partners in our development, who through their continued confidence, allow us to envision the diagnostics of tomorrow.

Our Strategy
A strategy putting patients first
Our strategy is focused on pathologies and meeting the needs of clinicians, patients and consumers. We concentrate on infectious diseases - in particular, sepsis, hospital-acquired infections, tuberculosis, AIDS, and hepatitis - as well as on tests delivering high medical value for cancers (breast, colon, prostate) and emergency cardiovascular diseases.
In applications for the agri-food, pharmaceutical and cosmetic industries, bioMérieux aspires to be the undisputed leader.

Corporate Social Responsibility
As a corporate citizen, bioMérieux has made a long-term commitment to the following actions:
• Improving access to diagnostics through our Public Health Department, focused on HIV/AIDS and tuberculosis.
• Supporting public health initiatives in limited-resource countries through the Mérieux foundations and our constant commitment to the programs of major international organizations.
• Upholding the Global Compact’s Principles: Since 2003, bioMérieux has been a member of the Global Compact, an international initiative under the auspices of the United Nations that aims to address the problems generated by globalization.
• Being active in the local communities of our sites and subsidiaries, supporting charitable and cultural initiatives.